Here are the DEF 14A proxy statements from Relmada Therapeutics, Inc. (RLMD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RLMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLMD filings page.
Relmada Therapeutics presents its 2026 annual meeting agenda and details a sharp 2025 turnaround after its prior lead program failed. The company shifted strategy to acquire de‑risked assets, adding NDV‑01 for non‑muscle invasive bladder cancer and sepranolone for Prader‑Willi syndrome and other uses.
Management highlights a share price recovery from $0.24 (about $7 million market cap) to $4.83 (about $353 million) and cash growth to about $100 million after a November financing. Stockholders will vote on re‑electing two directors, ratifying the auditor, adding 3.0 million shares to the 2021 equity plan, and increasing authorized common stock from 150,000,000 to 200,000,000.